Dendritic cells are antigen-presenting cells that are essential for the activation and proliferation of T cells. These cells can be used as a highly efficient anticancer treatment, but are extremely expensive. Current artificial dendritic cells are not as efficient due to inefficient multivalent binding of the antigens presented. This project aims to develop a more efficient synthetic dendritic cell by manipulation of the multivalency and molarity of the effector molecules (aCD3, aCD28 and cytokines) on a semiflexible polymer to facilitate effective T cell activation.

  Are you interested in a PhD at the AIBN? Click here, and start your journey today. 


Professor Alan Rowan
AIBN Institute Director
Senior Group Leader, Rowan Group

Dr Amanda Kijas
Senior Research Fellow, Rowan Group

Learn more about the
Rowan Group

Start your PhD journey
with AIBN